

IN THE CLAIMS

Claims 1 – 4 and 6 – 8 remain in the application. Claims 4 and 6 are amended. Claim 5 has been cancelled.

Please amend Claim 4 as follows:

Delete "for the treatment of disorders responsive to opening of KCNQ potassium channels"

Please cancel Claim 5.


Please amend Claim 6 as follows:

Delete "The method of claims 5" and replace with "A method for the treatment of disorders responsive to opening of the KCNQ potassium channels in a mammal in need thereof"

After "neurodegenerative orders" insert ", which comprises administering to said mammal a therapeutically effective amount of the compound of claim 1"

CLAIMS

1. (ORIGINAL) A compound of Formula I or a pharmaceutically acceptable salt thereof



wherein

R¹ is selected from the group consisting of straight or branched chain C₁₋₆ alkyl optionally substituted with amino, C₁₋₄ alkylamino or di(C₁₋₄ alkyl) amino, pyridinyl, pyrroolidinyl, piperidinyl, 2-thienyl, furanyl, imidazolyl, indenyl, benzofuran, C₃₋₆ cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl, and trifluoromethoxy;

A is -CH=CH-, 1,1-cyclopropyl, or -(CH₂)_n;

R² is C₁₋₄ alkyl, CF₃ or hydroxymethyl;


R³, R⁴, R⁵ and R⁶ each are independently hydrogen or fluoro;

n is an integer of 0 to 4, inclusive;

Het is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl and triazolyl optionally substituted with substituents independently selected from the group consisting of C₁₋₄ alkyl, halogen, amino and dimethylaminomethyl;

provided that when Het is pyridinyl, pyrimidinyl or pyrazinyl, then A is not -CH=CH-.

2. (ORIGINAL) The compound of claim 1 having the Formula Ic or a pharmaceutically acceptable salt thereof



wherein

R¹ is selected from the group consisting of straight or branched chain C₁₋₆ alkyl optionally substituted with amino, C₁₋₄ alkylamino or di(C₁₋₄ alkyl) amino, pyridinyl, pyrroldinyl, piperidinyl, 2-thienyl, furanyl, imidazolyl, indenyl, benzofuran, C₃₋₆ cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl, and trifluoromethoxy;

A is -CH=CH-, 1,1-cyclopropyl, or -(CH₂)_n-;

R² is methyl or hydroxymethyl;

R³, R⁴, R⁵ and R⁶ each are independently hydrogen or fluoro;

n is an integer of 0 to 4, inclusive;

Het is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl and triazolyl optionally substituted with substituents independently selected from the group consisting of C₁₋₄ alkyl, halogen, amino and dimethylaminomethyl;

provided that when Het is pyridinyl, pyrimidinyl or pyrazinyl, then A is not -CH=CH-.

3. (ORIGINAL) The compound of claim 1 selected from the group consisting of:

(S)-3-(2-fluoro-phenyl)-N-[1-(3-[1,2,4]triazol-1-yl-phenyl)-ethyl]-acrylamide;

(S)-3-(2-fluoro-phenyl)-N-[1-(3-thiazol-2-yl-phenyl)-ethyl]-acrylamide;

(S)-3-(2-fluoro-phenyl)-N-[1-(3-pyrazol-1-yl-phenyl)-ethyl]-acrylamide;

(S)-3-(2-fluoro-phenyl)-N-[1-(3-imidazol-1-yl-phenyl)-ethyl]-acrylamide;

(S)-4-phenyl-N-[1-(3-pyridin-3-yl-phenyl)-ethyl]-butyramide;

(S)-N-[1-(3-pyridin-3-yl-phenyl)-ethyl]-benzamide;

(S)-1H-imidazole-4-carboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;

(S)-N-[1-(3-imidazol-1-yl-phenyl)-ethyl]-3-phenyl-acrylamide;

(S)-N-[1-(3-oxazol-5-yl-phenyl)-ethyl]-3-phenyl-acrylamide;

(S)-3-phenyl-N-[1-(3-thiazol-2-yl-phenyl)-ethyl]-acrylamide;

(S)-3-phenyl-N-[1-(3-pyrazol-1-yl-phenyl)-ethyl]-acrylamide; and

(S)-benzofuran-2-carboxylic acid {1-[3-(6-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide; or a pharmaceutically acceptable salt thereof.

4. (CURRENTLY AMENDED) A pharmaceutical composition ~~for the treatment of disorders responsive to opening of KCNQ potassium channels~~ comprising a therapeutically effective amount of the compound of claim 1 in association with a pharmaceutically acceptable carrier, adjuvant or diluent.

5. (CANCELLED)

6. (CURRENTLY AMENDED) ~~The method of claims 5 A method for the treatment of disorders responsive to opening of the KCNQ potassium channels in a mammal in need thereof, wherein said disorders are acute and chronic pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders, which comprises administering to said mammal a therapeutically effective amount of the compound of claim 1.~~

7. (ORIGINAL) The method of claim 6 wherein said disorder is migraine.

8. (ORIGINAL) The method of claim 6 wherein said disorder is neuropathic pain.